...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>AIDS Research and Human Retroviruses >An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V.
【24h】

An efficient tool for surveying CRF01_AE HIV type 1 resistance in Thailand to combined stavudine-lamivudine-nevirapine treatment: mutagenically separated PCR targeting M184I/V.

机译：在泰国调查CRF01_AE HIV 1型对司他夫定-拉米夫定-奈韦拉平联合治疗的耐药性的有效工具：诱变分离的靶向M184I / V的PCR。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Under programs organized by the government of Thailand, HIV-1-infected patients have been treated since 2002 with several regimens, including a tablet known as GPOvir, which contains lamivudine, stavudine, and nevirapine. The aim of this study was to establish an effective assay, based on mutagenically separated PCR (MS-PCR), with the goal of surveying GPOvir-resistant HIV-1 cases. To determine the target mutation point for the assay, we analyzed the patterns of acquired drug resistance in plasma samples from GPOvir-failed cases. Of 428 HIV-1-infected individuals treated with GPOvir at Lampang Hospital in northern Thailand from 2002 to 2004, 66 had detectable viral loads after 3 months of treatment. The HIV-1 sequences of these 66 GPOvir-failed cases and 55 pre-GPOvir baseline samples were analyzed. The most prevalent drug resistance mutation among the samples was the lamivudine resistance M184I/V mutation. Based on this finding, we developed a new MS-PCR assay to detect the M184I/V mutation, and evaluated the assay performance for detecting GPOvir-resistant CRF01_AE cases. Comparing the results of M184I/V MS-PCR and sequence analyses, we found a concordance rate of 95% and an overall sensitivity of the M184I/V MS-PCR for detecting GPOvir-resistant cases of 79%. Considering the relatively low price of the assay, approximately Dollars 12.50 per sample, M184I/V MS-PCR may be a candidate for monitoring a large number of GPOvir-treated patients, particularly in developing nations.
机译：根据泰国政府组织的计划，自2002年以来，已对HIV-1感染患者进行了多种治疗，其中包括一种名为GPOvir的片剂，其中含有拉米夫定，司他夫定和奈韦拉平。这项研究的目的是建立一种基于诱变分离PCR（MS-PCR）的有效检测方法，目的是调查对GPOvir耐药的HIV-1病例。为了确定测定的目标突变点，我们分析了来自GPOvir失败病例的血浆样本中获得性耐药的模式。 2002年至2004年，在泰国北部兰邦医院用GPOvir治疗的428名HIV-1感染者中，经过3个月的治疗，可检测到病毒载量，其中66人具有可检测的病毒载量。分析了这66例GPOvir失败病例和55例GPOvir之前的基线样本的HIV-1序列。样品中最普遍的耐药性突变是拉米夫定耐药性M184I / V突变。基于此发现，我们开发了一种新的MS-PCR检测方法来检测M184I / V突变，并评估了检测耐GPOvir的CRF01_AE病例的检测性能。比较M184I / V MS-PCR和序列分析的结果，我们发现一致性检测率为95％，M184I / V MS-PCR检测GPOvir耐药病例的总体敏感性为79％。考虑到该测定的相对较低的价格，每个样品大约12.5美元，M184I / V MS-PCR可能是监测大量用GPOvir治疗的患者的候选者，尤其是在发展中国家。

著录项

相似文献

  • 外文文献
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号